Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Meco

JJ Watt Reacts to Texans’ Hiring Ex-Teammate DeMeco Ryans

The three-time NFL Defensive Player of the Year weighed in on his former team’s new head coach.

Sports Illustrated

J.J. Watt had an awesome reaction to the Texans hiring former teammate DeMeco Ryans as head coach

Watt has so much LOVE for his former teammate.

USA Today Sports Media Group

DeMeco Ryans Has a Defense Built Like Him

As they’ve cycled through quarterbacks, the 49ers’ top-ranked defense has remained a constant. It has everything to do with the man in charge of it and his younger self.

Sports Illustrated

From analysis to the latest developments in health,
read the most diverse news in one place.

Broncos defender D.J. Jones endorses coach candidate DeMeco Ryans

Broncos defensive lineman D.J. Jones endorses DeMeco Ryans for head coach job.

USA Today Sports Media Group

J.J. Watt gives endorsement of DeMeco Ryans as potential head coach

Watt believes 49ers defensive coordinator DeMeco Ryans 'will be a great head coach.'

USA Today Sports Media Group

Houston Texans need to hire 49ers DC DeMeco Ryans for these 3 reasons

@johnhcrumpler lists three key reasons why the Houston Texans should hire San Francisco 49ers defensive coordinator DeMeco Ryans as their next coach.

USA Today Sports Media Group

JJ Watt Supports Former Teammate DeMeco Ryans for Texans Job

The former Texans star knows who he wants Houston to hire.

Sports Illustrated

Read news from The Economist, FT, and more,
with one subscription

J.J. Watt endorses 49ers DC DeMeco Ryans as Texans coach

Former three-time NFL Defensive Player of the Year J.J. Watt endorses the idea of San Francisco 49ers DC DeMeco Ryans as Houston Texans coach.

USA Today Sports Media Group

ImmixBio's Lead Candidate Shows Improved Survival Over FDA-Approved Soft Tissue Cancer Drug

Immix Biopharma Inc (NASDAQ:IMMX) announced positive interim data from an animal study in Soft Tissue Sarcoma (STS). STS is a broad term for cancers that start in soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves). After one treatment cycle, ImmixBio's lead candidate IMX-110 produced 75% survival vs. 0% survival for…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.